Technology area: Biotechnology & Pharmaceuticals
3 pending office actions • 2 art units • 3 examiners • 0 of 3 (0%) have an AI response strategy ready • 1 patents granted in the last 365 days
Vesper Bio ApS is currently managing 3 pending office actions within the Biotechnology & Pharmaceuticals technology area. This number of actions indicates an active prosecution phase for the company's patent applications. The presence of 3 pending matters suggests that the company is working on multiple fronts to secure its intellectual property in the biotech sector.
The prosecution work is distributed among 3 distinct examiners and 2 distinct art units. This arrangement indicates that while the company is interacting with 3 different individuals, the technical subject matter is focused within 2 specific art units. Having 3 distinct examiners means that the company receives feedback from multiple perspectives, while the concentration in 2 art units suggests some technical overlap in the applications being prosecuted. This requires a strategy that is both examiner-specific and mindful of art unit trends.
JACKSON, SHAWQUIA is the busiest examiner for Vesper Bio ApS, responsible for 1 pending office action. Because each of the 3 pending office actions is assigned to a different examiner, the workload is evenly split. JACKSON, SHAWQUIA is one of the 3 distinct examiners currently reviewing the company's work. The outcome of the prosecution will be determined by the company's ability to address the specific concerns raised by each of these 3 examiners across the 2 art units.
Difficulty is derived from the rejection statutes on the most recent pending office action. §101-driven and multi-statute cases are graded Hard; §112-only and obviousness-type double-patenting cases are graded Easy; everything else is Medium. "Unknown" means we have not yet parsed a statute for that office action.
| Bucket | Cases |
|---|---|
| Multi-statute (no §101) | 3 (100%) |
How the docket's pending cases split across USPTO tech-center bands.
Manual office-action response work runs about 10 hours per case. The time-saved bands below show what IP Author's prosecution pipeline typically delivers — a conservative 20% on the low end, 35% in the middle, 50% on the high end.
| Examiner | Apps on this docket | Allow rate | Interview lift |
|---|---|---|---|
| JACKSON, SHAWQUIA | 1 | 78.0% | -3.4% |
| BURKETT, DANIEL JOHN | 1 | 63.4% | +33.2% |
| SAMSELL, RILLA MARIE | 1 | 69.1% | +6.4% |
Multi-statute / §101-driven matters, or cases in front of an examiner with an allow rate under 30%. The top 3 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18842375 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | JACKSON, SHAWQUIA | — |
| 18688974 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | BURKETT, DANIEL JOHN | — |
| 18556406 | MODULATORS OF SORTILIN ACTIVITY | SAMSELL, RILLA MARIE | — |
Cases in front of an examiner whose interview lift is 10 percentage points or more — i.e. interviewed cases historically resolve more favorably than non-interviewed ones. The top 1 ordered by deadline are shown.
| App # | Title | Examiner | Due in |
|---|---|---|---|
| 18688974 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | BURKETT, DANIEL JOHN | — |
| Art Unit | Apps |
|---|---|
| 1624 | 2 |
| 1626 | 1 |
| App # | Title | Examiner | Art Unit | Statutes | Status | Due in | AI | Filed |
|---|---|---|---|---|---|---|---|---|
| 18842375 | AMINO ACID BASED CARBAMATES AND/OR UREAS FOR THE TREATMENT OF SORTILIN DEPENDENT DISEASES | JACKSON, SHAWQUIA | 1626 | §102§112 | Non-Final OA | — | Pending | Aug 28, 2024 |
| 18688974 | 2-AMINO-5,5-DIMETHYLHEXANOIC ACID DERIVATIVES AS SORTILIN MODULATORS FOR USE IN THE TREATMENT OF DISEASE OF THE CENTRAL NERVOUS SYSTEM | BURKETT, DANIEL JOHN | 1624 | §102§112 | Non-Final OA | — | Pending | Mar 04, 2024 |
| 18556406 | MODULATORS OF SORTILIN ACTIVITY | SAMSELL, RILLA MARIE | 1624 | §102§112 | Non-Final OA | — | Pending | Oct 20, 2023 |
IP Author helps IP teams respond to office actions faster with AI-generated responses, examiner analytics, and prosecution intelligence.
Start Free TrialVesper Bio ApS has 3 pending office actions as of October 2026, spread across 2 art units and 3 examiners.
Shawquia Jackson has the most, with 1 of Vesper Bio ApS's pending office actions.
Mostly Biotechnology & Pharmaceuticals (USPTO Tech Center 1600), based on where its pending office actions are examined.
